Guggenheim reissued their buy rating on shares of Foamix Pharmaceuticals (NASDAQ:FOMX) in a research report released on Thursday morning. The brokerage currently has a $8.00 price objective on the specialty pharmaceutical company’s stock.

Several other research analysts have also recently commented on FOMX. HC Wainwright started coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, August 24th. They issued a buy rating and a $12.00 target price for the company. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 3rd.

Shares of Foamix Pharmaceuticals (FOMX) opened at $6.20 on Thursday. Foamix Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $11.27.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.90 million. During the same period in the prior year, the company earned ($0.19) EPS. Foamix Pharmaceuticals’s quarterly revenue was down 64.6% on a year-over-year basis. analysts forecast that Foamix Pharmaceuticals will post -1.34 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of FOMX. Marshall Wace North America L.P. grew its position in Foamix Pharmaceuticals by 42.7% in the 2nd quarter. Marshall Wace North America L.P. now owns 632,819 shares of the specialty pharmaceutical company’s stock worth $3,164,000 after purchasing an additional 189,350 shares during the last quarter. Bank of New York Mellon Corp grew its position in Foamix Pharmaceuticals by 38.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after purchasing an additional 151,849 shares during the last quarter. AXA grew its position in Foamix Pharmaceuticals by 14.1% in the 2nd quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock worth $4,374,000 after purchasing an additional 116,298 shares during the last quarter. PDT Partners LLC bought a new position in Foamix Pharmaceuticals in the 2nd quarter worth about $304,000. Finally, Renaissance Technologies LLC bought a new position in Foamix Pharmaceuticals in the 1st quarter worth about $307,000. Hedge funds and other institutional investors own 57.43% of the company’s stock.

WARNING: “Guggenheim Reaffirms Buy Rating for Foamix Pharmaceuticals (FOMX)” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/guggenheim-reaffirms-buy-rating-for-foamix-pharmaceuticals-fomx/1770487.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.